NCT01482884 - Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis | Biotech Hunter

Enrollment

147

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

June 30, 2013

Conditions

Ulcerative Colitis

Interventions

DRUG

tralokinumab

2 sc injections of every 2 weeks for 12 weeks.

DRUG

placebo

2 sc injections of every 2 weeks for 12 weeks.

Trial Locations (28)

Unknown

Research Site, České Budějovice

Research Site, Hradec Králové

Research Site, Olomouc

Research Site, Prague

Research Site, Amiens

Research Site, Caen

Research Site, Clichy

Research Site, Nice

Research Site, Pessac

Research Site, Rouen

Research Site, Vandœuvre-lès-Nancy

Research Site, Ludwigshafen

Research Site, Oelde

Research Site, Potsdam

Research Site, Wangen

Research Site, Florence

Research Site, Padua

Research Site, Roma

Research Site, Rozzano

Research Site, Bydgoszcz

Research Site, Częstochowa

Research Site, Lodz

Research Site, Sopot

Research Site, Warsaw

Research Site, Cambridge

Research Site, Coventry

Research Site, Oxford

Research Site, Shrewsbury